ASCENT1: A Phase 2 Trial to Evaluate the Efficacy and Safety of Oral Decitabine–Tetrahydrouridine (NDec) in Patients with Sickle Cell Disease

Speaker(s)

• 

  Biree Andemariam, MD

  Professor of Medicine
  New England Sickle Cell Institute, University of Connecticut Health, Farmington, CT, USA
  University of Connecticut Health
  Farmington, Connecticut, United States

First Author(s)

• 

  Biree Andemariam, MD

  Professor of Medicine
  New England Sickle Cell Institute, University of Connecticut Health, Farmington, CT, USA
  University of Connecticut Health
  Farmington, Connecticut, United States

Corresponding Author(s)

• 

  Biree Andemariam, MD

  Professor of Medicine
  New England Sickle Cell Institute, University of Connecticut Health, Farmington, CT, USA
  University of Connecticut Health
  Farmington, Connecticut, United States

Author(s)

• PH

  Pernille Højlund Nielsen, MS

  Statistician
  Novo Nordisk, Hovedstaden, Denmark
• RZ

  Rikke Zillmer, PhD

  Clinical Project Lead
  Novo Nordisk, Hovedstaden, Denmark
• JD

  Julie Derving Karsbøl, MD

  Senior International Medical Director
  Novo Nordisk, Hovedstaden, Denmark